9-溴-1-壬烯 | 89359-54-6

• 物质功能分类: 有机原料 - 烃类化合物及其衍生物 - 烃类卤化物
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 中文名称: 9-溴-1-壬烯
• 中文别名: 三异丙基硅基乙炔
• 英文名称: 9-bromo-1-nonene
• 英文别名: 9-bromonon-1-ene；1-bromo-8-nonene
• CAS: 89359-54-6
• 化学式: C₉H₁₇Br
• 分子量: 205.138
• InChiKey: RQXPBVHYVAOUBY-UHFFFAOYSA-N

物化性质

• 沸点：
  100-101℃/15mm
• 密度：
  1.1034 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  10
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

制备方法与用途

用途

9-溴-1-壬烯是合成乳腺癌药物氟维司群的一种反应物。

反应信息

• 作为反应物：
  描述：

  9-溴-1-壬烯 在 Schwartz's reagent 、 双氧水 、 溶剂黄146 、 lithium bromide 、 copper(ll) bromide 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 8.5h， 生成 氟维司群
  参考文献：
  名称：

  An alternative synthesis of the breast cancer drug fulvestrant (Faslodex®): catalyst control over C–C bond formation

  摘要：

  我们报告了一种重要的乳腺癌药物富维司特的四步合成方法，通过铜催化的1,6-加成来避免格氏试剂。

  DOI：

  10.1039/c5cc05805h
• 作为产物：
  描述：

  1,9-二溴壬烷 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 以55%的产率得到9-溴-1-壬烯
  参考文献：
  名称：

  评估ω-不饱和酸在卤代内酯化过程中的内外比。

  摘要：

  考察了2-（ω-烯基）苯甲酸与双（可力丁）碘和双（可力丁）溴六氟磷酸盐的反应。除了仅获得外泌内酯的2-丁-3-烯基苯甲酸外，对于其他酸，总是得到外泌内酯的混合物。内酯的比例对于11个碳原子的酸链长度（形成12元环内酯）和高于14个碳原子的酸链长度都很重要。在分子计算的基础上，通过电子和空间效应之间的竞争解释了内酯的形成。后者是通过跨环相互作用（对于酸链长度为8-11）和/或由链采用的构象（对于酸链长度>或= 14）形成的，这不利于外泌内酯的形成。

  DOI：

  10.1021/jo0017234

文献信息

• Monophosphine and diphosphine ligands for diplatinum polyynediyl complexes: Efficient syntheses of new functionality-containing systems and model compounds
  作者：Laura de Quadras、Jürgen Stahl、Fedor Zhuravlev、John A. Gladysz

  DOI：10.1016/j.jorganchem.2006.12.023

  日期：2007.4

  similarly yield R2P(CH2)mPR2 (m/R = 8/a, 95%; 14/a, 96%; 14/p-C6H4-t-Bu, 98%). Reactions of KPPh2 with Br(CH2)m′CHCH2and Br(CH2)7CH3 give the corresponding monophosphines Ph2P(CH2)m′CHCH2 (m′ = 7, 82%; 10, 84%) and Ph2P(CH2)7CH3 (85%). When the former is combined with [Pt(μ-Cl)(C6F5)(tht)]2 (tht = tetrahydrothiophene), trans-(C6F5)(Ph2P(CH2)m′CHCH2)2PtCl (77–70%) is isolated. When the latter (excess)

  Br（CH 2）4 Br和NaO（CH 2）2 CHCH 2在合适的条件下反应，生成Br（CH 2）4 O（CH 2）2 CHCH 2（55％），将其用KPPh 2处理后得到含醚的膦Ph 2 P（CH 2）4 O（CH 2）2 CHCH 2（83％）。CH 3 CH 2 OC（O）CHC（CH 3）2与BrMg（CH 2）3的反应在CuCl（cat。）和ClSiMe 3存在下的CHCH 2生成CH 3 CH 2 OC（O）CH 2 C（CH 3）2（CH 2）3 CHCH 2（67％），将其还原为醇将其溴化，与Grubbs的催化剂反应，氢化，并用KPPh 2处理，得到双（双甲基化）二膦Ph 2 P（CH 2）2 C（CH 3）2（CH 2）8 C（CH 3）2（通道2）2 PPh 2（整体47％）。I（CF 2）8 I和H 2 CCHCH 2 SnBu 3的光化学反应产生H 2 CCHCH
• Starting from Styrene: A Unified Protocol for Hydrotrifluoromethylation of Diversified Alkenes
  作者：Yi-Fei Yang、Jin-Hong Lin、Ji-Chang Xiao

  DOI：10.1021/acs.orglett.1c03630

  日期：2021.12.3

  In contrast with unactivated alkenes, the corresponding hydrotrifluoromethylation of styrene has remained challenging due to the strong propensity of styrene for oligomerization and polymerization. On the basis of our newly developed trifluoromethylation reagent, TFSP, herein we present a general method for the hydrotrifluoromethylation of styrene under photoredox catalysis. The substrate scope was

  与未活化的烯烃相比，由于苯乙烯具有强烈的低聚和聚合倾向，相应的苯乙烯氢三氟甲基化仍然具有挑战性。在我们新开发的三氟甲基化试剂 TFSP 的基础上，我们提出了一种在光氧化还原催化下苯乙烯氢三氟甲基化的通用方法。底物范围进一步扩展到未活化的烯烃、丙烯酸酯、丙烯酰胺和乙烯基杂原子取代的烯烃。通过相关的去质子三氟甲基化和三氟甲基三氟乙氧基化反应展示了该方法的可调性。
• Methods for using therapeutic compounds containing xanthinyl
  申请人：Cell Therapeutics, Inc.

  公开号：US06043250A1

  公开（公告）日：2000-03-28

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or 0, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  具有至少一个羧酸、酯或酰胺取代侧链的治疗化合物具有以下公式：CORE MOIETY --(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C(.sub.1-10)烷基、C(.sub.2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I：##STR1##其中：一个或两个p是整数一，否则p为二；n是从三到二十的整数；R.sub.1从取代和未取代的CH.sub.2；NR.sub.3中选择，R.sub.3为氢、取代或未取代的C(.sub.1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4连接形成具有四到七个环原子的取代或未取代杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从氢；卤素；取代或未取代的C.sub.(1-10)烷基；C.sub.(1-10)烷氧基；C.sub.(2-10)烯基；C.sub.(1-10)羟基烷基；--A(R.sub.5).sub.m中选择，A为N或0，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。R.sub.1中至少有一个为NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2为--A(R.sub.5).sub.m。这些化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定细胞内信号传导途径推进的疾病的治疗方法。
• Therapeutic compounds containing pyrimidinyl moieties
  申请人：Cell Therapeutics, Inc.

  公开号：US05807862A1

  公开（公告）日：1998-09-15

  Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY--(R).sub.j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.2 and R.sub.4 join to form a substituted or unsubstituted heterocycle having four to seven ring atoms, the ether group --O-- of --CHR.sub.4 O-- being a member of the heterocycle. R.sub.2 is selected from the group consisting of hydrogen; halogen; substituted or unsubstituted C.sub.(1-10) alkyl; C.sub.(1-10) alkoxyl; C.sub.(2-10) alkenyl; C.sub.(1-10) hydroxyalkyl; --A(R.sub.5).sub.m, A being N or O, m being one or two and R.sub.5 being hydrogen, a substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxyl, C.sub.(2-10) alkenyl or C.sub.(1-10) hydroxyalkyl), or carbocyclic or heterocyclic group. At least one of R.sub.1 is NR.sub.3, O or --CHR.sub.4 O--, or R.sub.2 is --A(R.sub.5).sub.m. The compounds and pharmaceutical compositions thereof are useful as therapies for diseases advanced via intracellular signaling through specific intracellular signaling pathways by mediating a signaling response to an external stimuli.

  具有至少一个羧酸、酯或酰胺取代侧链的治疗化合物具有以下公式：CORE MOIETY--(R).sub.j，其中j是从一到三的整数。核心基团是非环状或环状（碳环或杂环）。R可以从氢、卤素、羟基、氨基、取代或未取代的C.sub.(1-10)烷基、C.sub.(2-10)烯基、碳环或杂环基团中选择，至少一个R具有以下公式I：##STR1##其中：一个或两个p是整数一，否则p是二；n是从三到二十的整数；R.sub.1从取代和未取代的CH.sub.2；NR.sub.3中选择，R.sub.3为氢、取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基或C.sub.(1-20)羟基烷基，或碳环或杂环基团；O；--CHR.sub.4 O--，R.sub.4为取代或未取代的C.sub.(1-20)烷基、C.sub.(1-20)烷氧基、C.sub.(2-20)烯基、C.sub.(1-20)羟基烷基，或R.sub.2和R.sub.4结合形成具有四到七个环原子的取代或未取代杂环，--CHR.sub.4 O--的醚基--O--是杂环的成员。R.sub.2从氢、卤素、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基、C.sub.(1-10)羟基烷基；--A(R.sub.5).sub.m中选择，A为N或O，m为一或二，R.sub.5为氢、取代或未取代的C.sub.(1-10)烷基、C.sub.(1-10)烷氧基、C.sub.(2-10)烯基或C.sub.(1-10)羟基烷基，或碳环或杂环基团。R.sub.1中至少有一个为NR.sub.3、O或--CHR.sub.4 O--，或R.sub.2为--A(R.sub.5).sub.m。这些化合物及其制药组合物可用作通过介导对外部刺激的信号响应来通过特定细胞内信号传导途径推进的疾病的治疗方法。
• Fluorinated Musk Fragrances: The CF₂Group as a Conformational Bias Influencing the Odour of Civetone and (<i>R</i>)-Muscone
  作者：Ricardo Callejo、Michael J. Corr、Mingyan Yang、Mingan Wang、David B. Cordes、Alexandra M. Z. Slawin、David O'Hagan

  DOI：10.1002/chem.201600519

  日期：2016.6.6

  over edge locations in aliphatic macrocycles. In this study, the CF2 group has been introduced into musk relevant macrocyclic ketones. Nine civetone and five muscone analogues have been prepared by synthesis for structure and odour comparisons. X‐ray studies indeed show that the CF2 groups influence ring structure and they give some insight into the preferred ring conformations, triggering a musk odour

  二氟亚甲基（CF 2）基团在脂族大环化合物中具有在边缘位置转角的强烈趋势。在这项研究中，CF 2基已被引入到麝香相关的大环酮中。通过合成制备了九个西维酮和五个麝香酮类似物，用于结构和气味比较。X射线研究确实表明，CF 2基团会影响环的结构，并且使他们对首选的环构型有一些了解，从而触发了在专业香水环境中确定的麝香味。Bersuker及其同事对麝香香精的历史构象模型通常保持不变，并且由于CF 2的特殊放置而使结构偏离了这一共识。 群体，失去麝香的香味，变得不那么愉快。